April always brings with it a flurry of personnel changes. China FDA deputy commissioner Yin Li is heading to a leadership position in Sichuan province, Takeda COO Christophe Weber has become CEO and Otsuka has a new chairman, while personnel changes also took place at Aslan and CROs WuXiPRA and George Clinical.

Rheoscience focuses on target discovery in diabetes, obesity and the metabolic syndrome. To fund its target discovery activities, the company also provides preclinical research services, offering access to a range of novel animal models for validating experimental data and for use in the preclinical and early clinical phases of the drug discovery process.

In Vivo presents another installment of our quarterly review of dealmaking--in this case April through June 2002. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.